You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
SBC: 7 Hills Pharma LLC Topic: 102Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: Leukogene Therapeutics Inc. Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing an automated yeast dissection system for aging research
SBC: Innovative BioChips LLC Topic: NIAPROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE, LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and non-clinical GLP testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors.
SBC: Kiromic BioPharma, Inc. Topic: NHLBIAtheroSclerotic CardioVascular DiseaseASCVDis caused by inflammation within arteriesWhite blood cells enter the arterial wallsmacrophages become engorged with lipid cholesterol and summon other inflammatory cells to form plaques which ultimately rupture or occlude the arterykilling down stream tissuee gheart attackASCVD remains a major cause of morbidity and mortality of the elderlyCoronary artery ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD, LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration
SBC: RIDGELINE THERAPEUTICS LLC Topic: NIAIn the USthe number of individuals agedand older will increase byover the next decadeConcurrentlyMedicare costs are expected to double to treat chronic diseases that will plague this increasing number of older adultsOne of the most wide spread chronic diseases that affects older adults is sarcopeniawhich is observed inof adults overyears of age andof adults overyears of ageThis disease is characte ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and Production of Standardized Reference Diets for Zebrafish Research
SBC: Meridian Biotech, LLC Topic: 101The over arching goal of this Phase I SBIR proposal is to begin to optimize and implement standard reference diets for the ZebrafishDanio rerioan animal model of critical importance to the understanding of human health and development of vertebrate organismsA key problem in the industry is that standardized diets or feed management strategies have not been developed for Danio rerioThese diets are ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil
SBC: AcePre, LLC Topic: NCCIHPROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health